This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aveo Pharma: 'Crossover' Ate My Kidney Cancer Drug Survival Benefit

Tivozanib is under FDA review, with an approval decision expected by July 28.

To bolster the supportive case for approval, Aveo is also expected to point to other analyses from the phase III trial supporting tivozanib's efficacy in kidney cancer patients. Treatment with tivozanib following Nexavar resulted in a median progression-free survival of 8.4 months and a tumor response rate of 13%. Tivozanib-treated patients reported fewer side effects dose reductions than patients treated with Nexavar, but this did not translate into a significant difference in quality of life scores between the two drugs.

The median overall survival of 28.8 months reported by tivozanib-treated patients is similar to survival rates of competing kidney cancer drugs. In a recent study comparing Glaxo's Votrient to Pfizer's Sutent, median overall survival was 28.4 months and 29.3 months, respectively. Aveo has only compared tivozanib directly against Nexavar but is conducting another study right now that pits tivozanib against Sutent.

Multiple presentations of data from the tivozanib phase III study in kidney cancer are being presented later this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

If FDA approves tivoazanib, it will be the ninth drug marketed for kidney cancer and the fifth drug to share a similar mechanism of action. Sutent has been the market-leading kidney cancer drug but has recently lost ground to Votrient.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ONXX $0.00 0.00%
AVEO $1.24 0.00%
GSK $40.11 -0.67%
PFE $32.98 -0.72%
AAPL $111.79 0.17%


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs